ReviewTherapeutic advances in medical oncology2023
Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake.
Review in Therapeutic advances in medical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment.JCO precision oncology · 2026Article
- Article
- Article
- Evaluating the readability and quality of AI-generated scoliosis education materials: a comparative analysis of five language models.Scientific reports · 2025Article
- Hereditary Pancreatic Cancer: Advances in Genetic Testing, Early Detection Strategies, and Personalized Management.Journal of clinical medicine · 2025Review
- Should We Offer Universal Germline Genetic Testing to All Patients with Pancreatic Cancer? A Multicenter Study.Cancers · 2024Article
- Article
- Cancer, metastasis, and the epigenome.Molecular cancer · 2024Review
- Genetic and other risk factors for pancreatic ductal adenocarcinoma (PDAC).Familial cancer · 2024Review
- Expanding access to genetic testing for pancreatic cancer.Familial cancer · 2024Review
- Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma.Medicina (Kaunas, Lithuania) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prognosis is generally poor for patients with pancreatic ductal adenocarcinoma. However, patients with germline
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.